|

Iadademstat Clinical Trials

6 actively recruiting trials across 5 locations

Also known as: ORY 1001, ORY-1001, ORY-1001, RO7051790, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine

Irvine, California2 trials

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

Gilbert, Arizona1 trial

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Banner MD Anderson Cancer Center

Phase 1

Duarte, California1 trial

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

New Haven, Connecticut1 trial

Iadademstat + SBRT With Atezo in ES-SCLC

Yale University

Phase 1

Portland, Oregon1 trial

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.